Physicochemical Properties
| Molecular Formula | C22H25F8N5O8 |
| Molecular Weight | 639.449833631516 |
| Exact Mass | 639.157 |
| CAS # | 1374639-74-3 |
| Related CAS # | Gemigliptin;911637-19-9 |
| PubChem CID | 60199080 |
| Appearance | Light yellow to orange solid powder |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 19 |
| Rotatable Bond Count | 7 |
| Heavy Atom Count | 43 |
| Complexity | 880 |
| Defined Atom Stereocenter Count | 3 |
| SMILES | FC1(CCC(N(C1)C[C@H](CC(N1CC2C(=C(C(F)(F)F)N=C(C(F)(F)F)N=2)CC1)=O)N)=O)F.O[C@@H](C(=O)O)[C@H](C(=O)O)O |
| InChi Key | DPEZWSNXONTJHT-NDAAPVSOSA-N |
| InChi Code | InChI=1S/C18H19F8N5O2.C4H6O6/c19-16(20)3-1-12(32)31(8-16)6-9(27)5-13(33)30-4-2-10-11(7-30)28-15(18(24,25)26)29-14(10)17(21,22)23;5-1(3(7)8)2(6)4(9)10/h9H,1-8,27H2;1-2,5-6H,(H,7,8)(H,9,10)/t9-;1-,2-/m01/s1 |
| Chemical Name | 1-[(2S)-2-amino-4-[2,4-bis(trifluoromethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5,5-difluoropiperidin-2-one;(2R,3R)-2,3-dihydroxybutanedioic acid |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | IC50: 10.3 nM (human recombinant DPP-4)[2] |
| ln Vitro | With an IC50 of 11.69 mM, gemigliptin tartrate dose-dependently inhibits the formation of AGE-BSA[1]. ..With a Ki of 7.25 nM, gemigliptin tartrate is a competitive DPP-4 inhibitor[2]. |
| ln Vivo | In vivo, the production of AGEs and AGE cross-links is inhibited by gemigliptin tartrate (100 mg/kg; ig; daily; for 12 weeks|1]. In rats, dogs, and monkeys, gemigliptin tartrate dose-dependently suppresses plasma DPP-4 activity[2]. |
| Animal Protocol |
Animal/Disease Models: Male C57BL/KsJ-db/db mice (7 weeks old)[1] Doses: 100 mg/kg Route of Administration: Oral gavage, daily, for 12 weeks Experimental Results: Dramatically decreased circulating AGE levels by 44.5% in serum. |
| References |
[1]. Gemigliptin, a novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in vitro and in vivo. Eur J Pharmacol. 2014 Dec 5;744:98-102. [2]. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo. Eur J Pharmacol. 2016 Oct 5;788:54-64. |
Solubility Data
| Solubility (In Vitro) | DMSO: 100 mg/mL (156.38 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.91 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.91 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5638 mL | 7.8192 mL | 15.6384 mL | |
| 5 mM | 0.3128 mL | 1.5638 mL | 3.1277 mL | |
| 10 mM | 0.1564 mL | 0.7819 mL | 1.5638 mL |